Assessing patient accrual to cooperative group lung cancer trials: Why are rates disappointing?

Journal of Thoracic Oncology

Volumn 6, Issue 12, 2011, Pages 1971-1973

  Lally, Brian E ^a   Wagner, Henry ^b   Langer, Corey ^c   Thomas Jr , Charles R ^d  

^a UNIVERSITY OF MIAMI   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL SOCIETY; NATIONAL HEALTH ORGANIZATION; PATIENT ASSESSMENT; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

EID: 81755188357     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182370deb     Document Type: Editorial

References (5)

1. Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press, 2010.
2. Cox JD. The institute of medicine, the national cancer institute, and clinical trials. Int J Radiat Oncol Biol Phys 2011;79:1285-1286.
3. Harris G. U.S. Scrambling to Ease Shortage of Vital Medicine. The New York Times August 18, 2011. p. 2911.
4. Meropol NJ, Buzaglo JS, Millard J, et al. Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw 2007;5:655-664. (Pubitemid 47492764)
5. Curran WJ Jr, Schiller JH, Wolkin AC, et al. Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. Clin Lung Cancer 2008;9:222-226.